Nooshin Dalili
Tehran, Iran
NCT Number: NCT05212675
Treatment of dialysis patients involved with COVID-19 with short daily hemodialysis has been supposed to improve short term outcome. It is unclear if short daily dialysis would optimize mortality or ICU admission in routine dialysis patients with COVID-19.
Also the potential variants according with worse outcomes remain to be fully elucidated.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Tehran, Iran
investigators undertook a randomized trial in ESRD patients infected with COVID-19 to determine: 1) if short-daily hemodialysis is associated with a reduction in mortality and ICU admission in one weak period and; 2) the potential effective variants in worst outcome. . Paperwork for the trial was submitted to the shaheed beheshti university of medical sciences in June 2021 for registration . The protocol for this trial and supporting CONSORT checklist are available. The SBMU Ethics Board approved the study and all amendments. The study was conducted according to the Declaration of Helsinki.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7 days 2hours dialysis
Time frame: From date of randomization until the date of first documented progression or date of death
discharged or dead
Time frame: From date of randomization until the date of first documented progression or date of death
admission to ICU or not
Shahid Beheshti University of Medical Sciences
Other
Short Daily Versus Conventional Hemodialysis for COVID-19 Patients: A Randomized Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07128069
COVID-19, Coronaviridae Infections
Chicago, Illinois, United States
View Trial DetailsNCT07222384
COVID-19, Coronaviridae Infections
Palo Alto, California, United States
View Trial DetailsNCT05543616
COVID-19, Coronaviridae Infections
Birmingham, Alabama, United States
View Trial DetailsNCT05732116
COVID-19, Coronaviridae Infections
Ningbo, Zhejiang, China
View Trial Details